Table 5.
Previously Published Reports of ACP Tumors Profiling by NGS Methods
| Ser. No. | Number of Tumors | CTNNB1 Mutations | Custom Panels Used | NGS Platform Used | Reference |
|---|---|---|---|---|---|
| 1 | 12 | 11 Positives | Illumina TruSeq- WES | Illumina HiSeq 2500 | Brastianos et al,13 |
| 2 | 15 | 12 Positives | Targeted Sequencing | Roche- 454 GS-Junior | Marucci et al,21 |
| 3 | 1 | p. (Asp32Tyr) | Ampliseq Cancer Hotspot Panel v. 2 | Ion Torrent PGM | Ballester et al,30 |
| 4 | 3 | 2 Positives | 300 Cancer-related genes (Oncopanel) | Illumina Hiseq 2500 | Bi et al,34 |
| 5 | 26 | 26 Positives | Ion AmpliSeq Designer 23 genes | Ion Torrent PGM | Goschzik et al,33 |
| 6 | 10 | 8 Positives and Two- double mutations (FGFR3/CTNNB1) | Ion AmpliSeq Colon and Lung Panel v2 of 22 genes | Ion Torrent PGM | Bartels et al,32 |
| 7 | 31 | 21 Positives | AmpliSeq Targeted Sequencing | Ion Torrent PGM | Hara et al,31 |
| 8 | 1 | p. (Gly34Glu) | Illumina TruSEQ Amplicon Cancer Hotspot (47 genes) | Illumina MiSeq | Kassab et al,35 |
| 9 | 1 | p. (Thr41Ile) | Transcriptome (tumor RNA) Sequencing | Illumina HiSeq 2000 | Dahl et al,36 |